ZS Pharma developed Lokelma, a drug to treat hyperkalemia, a serious condition characterized by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases. Lokelma was approved for sale in 2018, and AstraZeneca has commercialized the drug in both Europe and the U.S.